Humanoid robots recently scrubbed in at UC San Diego and successfully removed gallbladders from live pigs, marking a world‑first teleoperated surgical milestone that investors in robotics, AI, and med‑tech will want on their radar.
When Wall Street Meets the Operating Room
For decades, robotic surgery meant hulking platforms like Intuitive Surgical’s (Nasdaq: ISRG) da Vinci system, a hospital showpiece that weighs roughly 816–1,800 kilograms and commands price tags in the $1.8–$2.5 million range. Those systems have delivered real clinical value, but required retrofitted operating rooms, deep capex budgets, and procedure volumes that made CFOs sweat spreadsheets.
UC San Diego’s humanoid experiment changes the visual and economic math: researchers teleoperated a 5‑foot, roughly 27–60 kilogram humanoid robot—nicknamed “Surgie”—to perform minimally invasive gallbladder removals on pigs, using standard laparoscopic tools and a headset‑and‑controller interface. This is a proof‑of‑concept, not a product launch, but it pushes general‑purpose humanoids out of the demo reel and into a real operating room, where outcomes and workflow—not backflips—matter.
The World’s First Humanoid‑Robot Surgery
In the trial, surgeons at UC San Diego completed two laparoscopic procedures on live non‑primate mammals using teleoperated humanoid robots. One operation paired a single humanoid with a human surgeon at the bedside; the second deployed two humanoid robots working side‑by‑side with no human physically at the table, still under direct remote control.
The procedures were detailed in Nature, noting that the robots maintained a virtual pivot point at the incision—a critical requirement in laparoscopic surgery—using visual markers and real‑time software, rather than rigid mechanical linkages. Frequent recalibration was needed during surgery due to breathing motion and robot movement, and the operations ran slower than a human surgeon, with about 156 milliseconds of control delay. Yet the team avoided conversion to open surgery and managed minor bile leakage and bleeding without serious complications, meeting the essential bar that this hardware can survive a real procedure, not just simulations.
From Backflips to Balance Sheets
Humanoid robots have spent most of the past few years doing viral stunts—parkour, dance routines, and cinematic factory demos that delighted social media but left hospital administrators unconvinced. UC San Diego’s group intentionally pivoted from spectacle to utility, arguing that the same embodied AI platforms can be pointed at life‑saving procedures in crowded, resource‑constrained operating rooms. Instead of bespoke arms designed around a single surgical task, Surgie starts from a general‑purpose humanoid form factor, adapted to grip standard surgical instruments through custom mounts. That means the same hardware could hand tools, clean, move equipment, and later step up to teleoperated surgery, essentially shifting humanoids from viral curiosities to billable clinical staff—albeit ones that never complain about call schedules.
The Surgical Robotics Stack: Old Guard vs. Upstarts
Intuitive Surgical Inc. (NASDAQ: ISRG) has long defined robot‑assisted surgery, pairing proprietary instruments, high‑end visualization, and a razor‑and‑blade business model. Newer players—from Medtronic plc (NYSE: MDT) to Asensus Surgical Inc. (NYSE American: ASXC)—are building alternative platforms, layering performance‑guidance software that nudges surgeons toward optimal moves.
A parallel frontier is emerging in humanoid surgery: Memic’s Hominis system, for example, won FDA De Novo authorization in 2021 for gynecologic procedures and features miniature humanoid‑shaped arms designed to mimic a surgeon’s shoulder, elbow, and wrist. LEM Surgical AG, a private firm in Switzerland, is building humanoid surgical robots powered by NVIDIA Corp.’s (NASDAQ: NVDA) Holoscan platform, targeting hard‑tissue procedures with real‑time AI processing. UC San Diego’s Surgie experiment sits at the intersection of these trends—combining humanoid morphology with teleoperation and off‑the‑shelf tools—to test whether “general‑purpose” can compete with hyper‑specialized hardware in the OR.
Why This Matters for Access and Margins
Two‑thirds of the world’s population lacks access to basic surgical care, and many countries operate with fewer than one trained surgeon per 100,000 people. Large, expensive systems such as da Vinci are difficult to deploy in rural hospitals, forward‑deployed military facilities, or ships, where floor space, power, and support staff are scarce. By contrast, a 27‑kilogram humanoid robot that costs a fraction of today’s platforms and fits anywhere a human assistant could stand can be paired with remote surgeons, effectively “extending” scarce expertise into remote operating rooms. For hospital operators, that raises the possibility of converting capital‑intensive, room‑locked robotics into a mobile fleet model, with teleoperated humanoids moving between sites as procedure demand—and reimbursement—dictate.
The Investor Lens: Platforms, Not Just Products
For public‑market investors, the early winner likely won’t be a single surgical robot, but the ecosystem that powers multiple platforms. NVIDIA’s Holoscan, for example, is already embedded in LEM Surgical’s humanoid system, providing sensor fusion and AI inference in real time. Companies like NVIDIA Corp. (NASDAQ: NVDA) could benefit as more surgical and humanoid developers standardize on common compute and perception stacks. On the device side, Intuitive Surgical Inc. (NASDAQ: ISRG) retains scale advantages, regulatory experience, and entrenched surgeon workflows, but faces a landscape where humanoid systems, teleoperation, and AI‑guided navigation may erode the moat from the edges rather than head‑on. Thematically, investors may gravitate toward baskets that combine surgical hardware (ISRG, MDT, ASXC), enabling AI platforms (NVDA and peers), and specialized private‑market exposure where humanoid surgery is being incubated, via venture or crossover vehicles.
Risk Factors: What Could Go Wrong?
Teleoperated humanoid surgery today is slower than human hands, with lag and calibration drift that forced pauses mid‑procedure. On top of that, sterilization, reliability, and liability frameworks for general‑purpose humanoids in the OR remain unresolved, and regulators will likely demand extensive animal and early human data before granting approvals. There’s also a human‑capital risk: surgeons must be trained on remote control interfaces and trust systems that may feel closer to game controllers than to traditional instruments, while hospital boards must weigh new cybersecurity and uptime concerns for network‑dependent platforms. If the technology stumbles in high‑profile trials or proves too complex to maintain outside major centers, adoption curves—and associated revenue ramps—could flatten quickly.
The Long Game: From Proof‑of‑Concept to Standard of Care
The first robot‑assisted gallbladder removal in the late 1990s reportedly took hours; today, similar procedures are often completed in roughly 30 minutes as platforms, techniques, and training matured. Researchers behind Surgie explicitly draw that comparison, arguing that slow, slightly messy early operations aren’t a bug—they’re the starting line. UC San Diego’s team expects humanoids to enter the OR first as assistants—handing tools, cleaning, repositioning equipment—before moving up the value chain to teleoperated surgeries in settings where surgeon shortages are most acute. Over time, hybrid human‑robot teams could create a stratified model of care: local staff handling pre‑op and post‑op workflows, while remote specialists, aided by AI guidance, perform the high‑skill procedures through portable humanoid platforms.
From an investor’s standpoint, the key is to watch for inflection points—regulatory milestones like new FDA clearances, hospital pilots that move from marketing headlines to billable procedures, and early data on cost per case and complication rates. When humanoid surgery stops being a curiosity and starts showing up in earnings calls and line items, the story shifts from sci‑fi to cash flow.
The Sources
- UC San Diego News Center – “Surgeons Use Teleoperated Humanoid Robots to Perform Live Surgery, a World First”
https://today.ucsd.edu/story/surgeons-use-teleoperated-humanoid-robots-to-perform-live-surgery-a-world-first - UCSD Advanced Robotics & Controls Lab – Project Video and Overview: “Humanoid Robots Used to Perform a World’s First Teleoperated Robotic Surgery”
https://www.youtube.com/watch?v=Dk7WVAcyNis - Nature / arXiv – “In vivo feasibility study of humanoid robots in surgery” (preprint)
https://arxiv.org/html/2607.07972v1 - Particle News – “Teleoperated Humanoid Robots Complete Two Live Surgeries in UC San Diego Preclinical Trial”
https://particle.news/story/teleoperated-humanoid-robots-complete-two-live-surgeries-in-uc-san-diego-preclinical-trial - Ars Technica / Cor.ax summary – “Humanoid robots remove pig gallbladders in teleoperated surgery trial”
https://cor.ax/links/88734 - Intuitive Surgical – Da Vinci Xi Robotic Surgical System (product page)
https://www.intuitive.com/en-us/products-and-services/da-vinci/xi - Intuitive Surgical – Da Vinci 5 Surgical System (overview and indications)
https://www.intuitive.com/en-gb/- - Intuitive Surgical – Da Vinci Xi Robotic Surgical System (global site variant)
https://www.intuitive.com/en-in/products-and-services/da-vinci/xi - Memic Innovative Surgery – FDA De Novo Authorization for Hominis Robot‑Assisted Surgical Platform
https://www.biospace.com/memic-receives-fda-de-novo-marketing-authorization-for-first-ever-surgical-robotic-system-with-humanoid - LEM Surgical AG – “LEM Surgical Builds Humanoid Surgical Robotics Powered by NVIDIA Holoscan”
https://www.theglobeandmail.com/investing/markets/markets-news/ACCESS%20Newswire/31464246/lem-surgical-builds-humanoid-surgical-robotics-powered-by-nvidia-holoscan - Medical Robotics Landscape – “16 Surgical Robotics Companies You Need to Know”
https://www.massdevice.com/16-surgical-robotics-companies-you-need-to-know/ - UC San Diego Teleoperated Humanoid Surgery – Additional Coverage and Technical Summary
https://roboticsintl.com/article/uc-san-diego-completes-first-surgical-procedures-using-teleoperated-humanoid-rob
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.
